← Markets

OPKO Health, Inc.

OPK · NASDAQ

Market closed$1.19$0.00 (0.00%)After hours $1.19 · 0.00%

Key statistics

Previous close$1.19
Open$1.19
Day high$1.22
Day low$1.18
52-week high$1.61
52-week low$0.980000
Market cap898.56M
Volume1.73M
Average volume2.77M
P/E ratio-4.41
Forward P/E—
EPS-0.27
Dividend yield0.00%

Market context

Why it moved

OPK showed no significant price movement today, trading flat with minimal change from its previous close as no major company-specific news or catalysts emerged to drive directional activity.

InstagramStockinvestPremomIndeedFacebook

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026OPKO Health closed modestly lower, slipping against a broader healthcare sector that found support from UnitedHealth Group's strong Q2 earnings beat and raised guidance, which lifted managed care and adjacent names. Despite a positive tailwind for biotechnology peers—the sector is up roughly 12-13% on average since Q1 earnings—OPKO has yet to benefit materially, reflecting ongoing investor caution around the company's near-term catalysts. UBS has flagged healthcare as a key allocation focus for Q3, citing improving earnings revisions, a stabilizing regulatory environment, and a pickup in biotech M&A activity, though smaller-cap names like OPKO remain on the periphery of that rotation.

-0.8333

July 16, 2026OPKO Health closed modestly lower amid cautious analyst sentiment, with Zacks Research recently cutting its Q2 EPS estimate and the stock carrying an average 'Reduce' rating with a consensus price target of $1.55. The company's last quarterly results showed revenue of $124.2M, missing estimates by ~5% and falling 17.1% year-over-year, while the broader healthcare sector drew UBS's positive attention as a key allocation focus for H2 2026, potentially offering limited near-term relief for OPKO given its persistent earnings losses and below-average sector momentum.

-1.6393

July 15, 2026OPKO Health shares closed modestly lower, edging down alongside a mixed healthcare sector backdrop as Wall Street maintains a cautious stance on the stock. Analyst sentiment remains subdued following Zacks Research's recent downward revision to Q2 EPS estimates and a consensus 'Reduce' rating, with the company's last quarterly revenue of $124.2M falling short of expectations and declining 17.1% year over year. With a deeply negative full-year EPS outlook of -$0.29 and Q2 earnings on the horizon, investors continue to weigh the company's path to profitability amid broader biotech headwinds and sector-wide earnings scrutiny.

-0.813

July 14, 2026OPKO Health closed sharply lower, plunging nearly 9% on above-average volume—nearly double the daily average—as analyst pressure mounted with Zacks Research cutting its Q2 EPS estimate and the consensus outlook remaining deeply negative at -$0.29 per share for the full year. The move came against a difficult backdrop for the broader healthcare sector, with XLV under pressure ahead of key Q2 earnings from major sector constituents, and biotech specifically forecast to see a 79% earnings drop. In after-hours trading, shares have partially recovered, edging up about 1.6%.

-8.8889

July 11, 2026OPKO Health shares declined nearly 3% on Thursday, underperforming a healthcare sector that has been broadly celebrated as a market leader, with Jim Cramer recently calling biotech "the hottest group in the market." The broader XLV sector ETF pulled back from its session highs while the S&P 500 closed near 52-week highs. Headwinds for small-cap biotechs like OPKO include looming Medicaid cuts tied to the One Big Beautiful Bill Act, which analysts warn will make revenue projections "less sunny" and could cause investors to gravitate toward lower-risk, later-stage assets.

-2.8777

July 9, 2026OPKO Health shares tumbled over 5% as a broad risk-off selloff swept markets following President Trump's declaration that the U.S.-Iran ceasefire was "over," sending oil prices surging and triggering a flight from speculative and small-cap biotech names. The decline came despite a broadly bullish backdrop for healthcare and biotech, with Jim Cramer recently calling biotech "the hottest group in the market" and predicting a wave of M&A deals under the more favorable regulatory environment — a tailwind that has yet to lift OPKO, which remains a sub-$2 micro-cap with limited near-term catalysts to offset macro headwinds.

-5.3691

July 3, 2026OPKO Health closed modestly lower as investors digested a recent Schedule 13D/A filing confirming that Chairman and CEO Phillip Frost maintains a 34.1% beneficial stake in the company — a disclosure driven by an updated share count rather than new open-market purchases. Analysts maintain a consensus price target of $3.40, framing shares as materially undervalued at current levels, though the company continues to report losses and trades at a price-to-sales premium relative to peers. In after-hours trading, shares edged back up nearly 2%, while the broader healthcare sector (XLV) closed near 52-week highs, providing a supportive macro backdrop.

-0.6536

July 2, 2026OPKO Health shares rose 2% as investors digested a Schedule 13D/A filing from Chairman and CEO Phillip Frost confirming his 34.1% beneficial ownership stake in the company — a position maintained through trusts, stock options, and restricted stock units. The filing, triggered solely by an update to OPKO's outstanding share count (now 746.3 million shares as of June 29), reflects no new purchases or sales by Frost in the prior 60 days, signaling continued insider alignment rather than fresh buying interest. The move came alongside a broadly supportive day for healthcare, with the sector ETF XLV holding near its session highs even as tech and chip stocks dragged the broader market lower to start the new quarter.

2

Simply Wall Street · June 11, 2026Should OPKO’s New 15% Nicoya Stake and RAYALDEE Terms Require Action From OPKO Health (OPK) Investors?Stock Titan · April 30, 2026Kidney drug RAYALDEE targets China as OPKO takes 15% Nicoya stakeOPKO Health, Inc. · April 28, 2026OPKO Health Reports First Quarter 2026 Business Highlights and Financial ResultsOPKO Health, Inc. · February 26, 2026OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
Benzinga · June 16, 2026Entera Bio Reports Preclinical Results For Oral Peptide Programs EB612 And EB618, Advancing Toward Clinical Development
Benzinga · April 30, 2026OPKO Health Subsidiary EirGen Pharma Expands Agreement With Nicoya Therapeutics To Commercialize RAYALDEE In China
Mt Newswire · April 29, 2026Barrington Downgrades OPKO Health to Market Perform From Outperform
Benzinga · April 29, 2026Barrington Research Downgrades OPKO Health to Market Perform
Benzinga · April 29, 2026OPKO Health Q1 2026 Earnings Call: Complete Transcript
Mt Newswire · April 28, 2026Earnings Flash (OPK) OPKO Health Posts Q1 Loss of $0.07 per Share, vs. FactSet Est of $0.07 Loss
Benzinga · April 28, 2026OPKO Health Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $551.214M Est
Mt Newswire · April 28, 2026Earnings Flash (OPK) OPKO Health, Inc. Reports Q1 Revenue $124.2M, vs. FactSet Est of $130.5M

Peers

S&P 500SPX · $7,457.69-1.01%Celldex Therapeutics, Inc.CLDX · $35.35-0.14%BioCryst Pharmaceuticals, Inc.BCRX · $9.29+2.03%Myriad Genetics, Inc.MYGN · $6.18-0.16%Teva Pharmaceutical Industries LimitedTEVA · $32.03-0.59%Guardant Health, Inc.GH · $155.87+0.56%Labcorp Holdings Inc.LH · $283.36+0.50%Innoviva, Inc.INVA · $21.71-2.25%AMN Healthcare Services, Inc.AMN · $35.00+2.28%Omada HealthOMDA · $23.70+0.13%Innovage Holding Corp.INNV · $11.50-3.12%Agenus Inc.AGEN · $5.01+0.20%